Omdia: Global Cloud Infrastructure Spending Hits $102.6 Billion, up 25% in Q3 2025
LONDON–(BUSINESS WIRE)–#Cloud–According to new research from Omdia, global spending on cloud infrastructure services reached $102.6 billion in... Read more.
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch
TOKYO–(BUSINESS WIRE)–#axelspace–Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within... Read more.
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.
TOKYO–(BUSINESS WIRE)–#axelspace–Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within... Read more.
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease
CADEMPINO, Switzerland–(BUSINESS WIRE)–#ClinicalTrial—Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build... Read more.
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER study In MANEUVER, pimicotinib significantly improved... Read more.
KKR Launches European Rail Leasing Platform with Green Mobility Partners
Strategic partnership to scale newly established locomotive and train leasing company into a leading European rail leasing platform FRANKFURT, Germany–(BUSINESS... Read more.
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER study In MANEUVER, pimicotinib significantly improved... Read more.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
TOKYO–(BUSINESS WIRE)–$INCY–Incyte Biosciences Japan G.K. today announced approval from Japan’s Ministry of Health, Labour and Welfare (MHLW)... Read more.
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
TOKYO–(BUSINESS WIRE)–$INCY–Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz®... Read more.
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–The first patient has been dosed in the DESTINY-Endometrial02 phase 3 trial evaluating ENHERTU® (trastuzumab... Read more.